A randomized comparison study of intravesical mitomycin C versus mitomycin C and cytarabine to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder.

A randomized comparison study of intravesical mitomycin C versus mitomycin C and cytarabine to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder. - A Randomized comparison study of intravesical MMC vs MMC+Ara-C in NMIBC.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008173

Enrollment

200

Registered

2012-06-18

Start date

2012-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

Mitomycin C 30mg 1/week for 6 weeks Mitomycin C 30mg+cytarabine 200mg 1/week for 6 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-muscle invasive bladder cancer that were treated with transurethral resection.

Exclusion criteria

Exclusion criteria: 1) WHO prformance status is 3 or more. 2) Contraindication of drugs. 3) With other maligancy and plan of additional treatment. 4) With disadvantage for patient by outpatinet care. 5) Not include urothelial cancer by hitological diagnosis. 5) Without a written agreement. 6) Under 20 years old.

Design outcomes

Primary

Measure	Time frame
Disease-free survival	—

Countries

Japan

Contacts

Public ContactYasuyoshi Miyata

Nagasaki University Hospital Urology

int.doc.miya@m3.dion.ne.jp095-819-7340

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026